<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02718300</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 50465-201</org_study_id>
    <secondary_id>Parsaclisib</secondary_id>
    <nct_id>NCT02718300</nct_id>
  </id_info>
  <brief_title>A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis</brief_title>
  <official_title>A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and efficacy of the&#xD;
      combination of parsaclisib and ruxolitinib in subjects with myelofibrosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 8, 2017</start_date>
  <completion_date type="Anticipated">November 12, 2021</completion_date>
  <primary_completion_date type="Actual">January 14, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2, Part 3 and Part 4: Change From Baseline in Spleen Volume at Week 12 as measured by MRI or CT scan</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events (AEs) and changes in vital signs, ECGs, and laboratory parameters</measure>
    <time_frame>Screening through up to 30 days after last dose of study drug, up to 25 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total symptom score as measured by patient-reported myelofibrosis symptoms</measure>
    <time_frame>Baseline through Week 12 or Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Spleen Volume at Week 24 as measured by MRI or CT scan</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>MPN (Myeloproliferative Neoplasms)</condition>
  <arm_group>
    <arm_group_label>Part 1: Ruxolitinib + Parsaclisib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial cohort dose of parsaclisib added to existing stable regimen of ruxolitinib, with subsequent cohort escalations based on protocol-specific criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Ruxolitinib + Parsaclisib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2 will compare 2 doses of parsaclisib .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: Ruxolitinib + Parsaclisib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 3 will compare 2 different long term dosing strategies.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 4: Ruxolitinib + Parsaclisib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 4 will compare 2 different daily dosing strategies.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Parsaclisib</intervention_name>
    <description>Up to 3 oral once a day (QD) doses of parsaclisib. Doses will be taken once daily for 8 weeks, followed by once weekly dosing at the same dose level.</description>
    <arm_group_label>Part 1: Ruxolitinib + Parsaclisib</arm_group_label>
    <other_name>INCB050465</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Parsaclisib</intervention_name>
    <description>Two recommended oral QD doses of parsaclisib. Once daily doses of parsaclisib will be taken for 8 weeks, followed by once weekly dosing at the same dose level.</description>
    <arm_group_label>Part 2: Ruxolitinib + Parsaclisib</arm_group_label>
    <other_name>INCB050465</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <description>The dose of ruxolitinib will be that which the subjects had been taking for at least 8 weeks before the first dose of parsaclisib.</description>
    <arm_group_label>Part 1: Ruxolitinib + Parsaclisib</arm_group_label>
    <arm_group_label>Part 2: Ruxolitinib + Parsaclisib</arm_group_label>
    <arm_group_label>Part 3: Ruxolitinib + Parsaclisib</arm_group_label>
    <arm_group_label>Part 4: Ruxolitinib + Parsaclisib</arm_group_label>
    <other_name>Jakafi®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Parsaclisib</intervention_name>
    <description>20 mg oral QD dose of parsaclisib for 8 weeks. After 8 weeks patients will take either 20 mg once weekly or 5 mg once daily.</description>
    <arm_group_label>Part 3: Ruxolitinib + Parsaclisib</arm_group_label>
    <other_name>INCB050465</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Parsaclisib</intervention_name>
    <description>2 dose strategies will be compared:&#xD;
5 mg parsaclisib beginning on Day 1 until end of treatment.&#xD;
20 mg oral QD dose of parsaclisib for 8 weeks; after 8 weeks patients will take 5 mg once daily.</description>
    <arm_group_label>Part 4: Ruxolitinib + Parsaclisib</arm_group_label>
    <other_name>INCB050465</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of primary myelofibrosis, post-polycythemia vera myelofibrosis, or&#xD;
             post-essential thrombocythemia myelofibrosis&#xD;
&#xD;
          -  Palpable spleen of &gt; 10 cm below the left subcostal margin on physical examination at&#xD;
             the screening visit OR&#xD;
&#xD;
          -  Palpable splenomegaly of 5 to 10 cm below left subcostal margin on physical exam AND&#xD;
             active symptoms of MF at the screening visit as demonstrated by presence of 1 symptom&#xD;
             score ≥ 5 or 2 symptom scores ≥ 3 using the Screening Symptom Form&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of experimental drug therapy for myelofibrosis, or any other standard drug (eg,&#xD;
             danazol, hydroxyurea, etc) with the exception of ruxolitinib within 6 months of&#xD;
             starting study (combination) therapy and/or lack of recovery from all toxicities from&#xD;
             previous therapy (except ruxolitinib) to Grade 1 or better&#xD;
&#xD;
          -  Inability to swallow food or any condition of the upper gastrointestinal tract that&#xD;
             precludes administration of oral medications&#xD;
&#xD;
          -  Unwillingness to be transfused with blood components&#xD;
&#xD;
          -  Recent history of inadequate bone marrow reserve as demonstrated by the following:&#xD;
&#xD;
               -  Platelet count &lt; 50 × 10^9/L in the 4 weeks before screening or platelet&#xD;
                  transfusion(s) within 8 weeks before screening&#xD;
&#xD;
               -  Absolute neutrophil count levels &lt; 0.5 × 10^9/L in the 4 weeks before screening&#xD;
&#xD;
               -  Subjects with peripheral blood blast count of &gt; 10% at the screening or baseline&#xD;
                  hematology assessments&#xD;
&#xD;
               -  Subjects who are not willing to receive red blood cell (RBC) transfusions to&#xD;
                  treat low hemoglobin levels&#xD;
&#xD;
          -  Inadequate liver function at screening as demonstrated by the following:&#xD;
&#xD;
               -  Direct bilirubin ≥ 2.0 × the upper limit of laboratory normal (ULN). (NOTE:&#xD;
                  direct bilirubin will only be determined if total bilirubin is ≥ 2.0 × ULN)&#xD;
&#xD;
               -  alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 2.5 × ULN&#xD;
&#xD;
          -  Inadequate renal function at screening as demonstrated by creatinine clearance &lt; 50&#xD;
             mL/min or glomerular filtration rate &lt; 50 mL/min/1.73 m^2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Assad, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Birmingham Hematology &amp; Oncolgy Associates Llc</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alta Bates Medical Center</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Cancer Associates For Research and Excellence</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pcr Oncology</name>
      <address>
        <city>Pismo Beach</city>
        <state>California</state>
        <zip>93449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Cancer Assoc. for Research and Excellence</name>
      <address>
        <city>San Marcos</city>
        <state>California</state>
        <zip>92069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shands Hospital</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Blood and Marrow Transplantation</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McFarland Clinic</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Agnes Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center For Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Medical Group</name>
      <address>
        <city>Florham Park</city>
        <state>New Jersey</state>
        <zip>07932</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Mexico Cancer Care Alliance</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care, Inc.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Scott and White Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Md Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Centers of South Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renovatio Clinical Consultants Llc</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Va Salt Lake City Health Care System</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vista Oncology Inc Ps</name>
      <address>
        <city>Olympia</city>
        <state>Washington</state>
        <zip>98506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 21, 2016</study_first_submitted>
  <study_first_submitted_qc>March 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2016</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary myelofibrosis (PMF)</keyword>
  <keyword>post-polycythemia vera myelofibrosis (PPV-MF)</keyword>
  <keyword>post-essential thrombocythemia myelofibrosis (PET-MF)</keyword>
  <keyword>myeloproliferative neoplasms (MPNs)</keyword>
  <keyword>phosphoinositide 3-kinase (PI3K) inhibitor</keyword>
  <keyword>Janus kinase (JAK) inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

